ThyroSeq v3 的良性判读率与分子检测结果分布
总体 BCR 为 74.1%(166/224),AUS/FLUS 类别 BCR 较高,RAS 突变是最常见的阳性结果。高 BCR 表明 ThyroSeq v3 可能有效避免大多数「阴性」不确定病例的手术。
要点
- ThyroSeq v3 在不确定甲状腺结节中总体 BCR 为 74.1%。
- AUS/FLUS 类别的 BCR 高于其他不确定诊断类别。
- RAS 突变是最常见的阳性分子结果。
核心结论
- ThyroSeq v3 的高 BCR 表明其可能有效避免大多数「阴性」不确定病例的手术,同时为阳性病例提供风险评估并指导临床管理。
研究设计与样本
- 排除检测到甲状旁腺和髓样癌分子标志物的病例以及分子检测不合格或有限的病例,最终纳入 224 例不确定病例。
主要发现
- 224 例不确定病例中,ThyroSeq v3 总体 BCR 为 74.1%(166/224)。
- AUS/FLUS 类别的 BCR 高于其他不确定诊断类别。
- RAS 突变是最常见的阳性结果。
关键数值与推荐
- 总体 BCR 为 74.1%(166/224 例)。
- AUS/FLUS 类别 BCR 高于其他不确定诊断类别。
- RAS 突变为最常见的阳性结果。
临床怎么用
- 对于 ThyroSeq v3 检测结果为「阴性」的不确定甲状腺结节,可考虑类似良性细胞学诊断进行管理,避免不必要的手术。
- 对于阳性结果,可依据分子风险分层指导临床管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The benign call rate (BCR) is the percentage of cytomorphologically indeterminate cases with subsequent benign or negative molecular results. For rule-out tests, the BCR is an important parameter because these molecular "negative" cases may be managed similarly to those with a benign cytology diagnosis. Although earlier versions of ThyroSeq molecular tests were less effective in excluding malignancy, the extensively expanded v3 version with a high negative predictive value is considered to represent a rule-out test. In the current study, the authors evaluated the BCR and the overall molecular result distribution of ThyroSeq v3. METHODS: All indeterminate thyroid fine-needle aspiration cases (except those deemed suspicious for malignancy) with available ThyroSeq v3 results from November 2017 to June 2018 were retrieved from the cytopathology files. Because the ThyroSeq v3 genomic classifier was designed for thyroid follicular-derived lesions, cases in which parathyroid and medullary carcinoma molecular markers were detected and those that were inadequate or limited for molecular testing were excluded from the study. For the remaining cases, the indeterminate diagnoses were correlated with molecular and histologic results. RESULTS: Among the 224 indeterminate cases (except those deemed suspicious for malignancy), the overall ThyroSeq v3 molecular test BCR was 74.1% (166 of 224 cases). The category of atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) had higher BCRs compared with the other indeterminate diagnostic categories. RAS mutations were the most common positive results. CONCLUSIONS: The high BCR demonstrates that ThyroSeq v3 is potentially effective in sparing the large majority of indeterminate cases with "negative" results from surgery while offering risk assessment for the positive cases and guiding clinical management.
引用
- Ohori NP, Landau MS, Carty SE, et al. Benign call rate and molecular test result distribution of ThyroSeq v3. Cancer Cytopathol. 2018. PMID: 30561907. doi:10.1002/cncy.22088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。